Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BeiGene

< Previous 1 2 3 Next >
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
From BeiGene
Via Business Wire
Tickers BGNE
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Appoints Chan Lee as General Counsel
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
Tickers BGNE
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene
Via Business Wire
Tickers BGNE
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
From BeiGene
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.